Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Abpro is a clinical-stage biotechnology company focused on developing next-generation antibody therapeutics for cancer, ophthalmology, and infectious diseases. The company utilizes its proprietary DiversImmune and MultiMab platforms to engineer bispecific and monospecific antibodies with enhanced efficacy and safety profiles. Its lead programs include bispecific antibodies targeting HER2 and CD3 for solid tumors, as well as therapies for wet age-related macular degeneration and COVID-19. Abpro has established strategic partnerships with global pharmaceutical companies like Celltrion and Essex Bio-Technology to advance its pipeline. The company is headquartered in the biotechnology hub of Lexington, Massachusetts, and is currently transitioning to a public entity through a SPAC merger.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Alta Pharma.